Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Novavax to sell Czech manufacturing unit to Novo Nordisk
Novo Nordisk keeps manufacturing expansion spree rolling with plans for $400M quality hub in Denmark
Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...
The acquisition by the Danish holdings company (owner of pharmaceutical giant Novo Nordisk) has attracted scrutiny from ...
Three separate asset management firms launched exchange-traded funds on Tuesday, unveiling products focused on securitized ...
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...
Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback